Medical Devices

With promising preclinical data and Australian trial approval, Kivu’s KIVU-305 aims to overcome past failures in targeting aggressive solid tumors.

New subgroup data from ITM's COMPETE trial could refine treatment for a tough-to-treat cancer and bolster the company's position in the radiopharma market.

As Evolus presents at a key healthcare conference, investors watch to see if its new filler line and digital strategy can deliver on bold promises.

Investors sue Corcept Therapeutics, claiming the company hid FDA warnings about its key drug, relacorilant, before a 50% stock price collapse.

Plus Therapeutics' REYOBIQ gains a crucial CPT code, a vital step in bringing this targeted radiotherapy to patients with aggressive brain cancers.

Medtech giant reveals its 'Magnificent Seven' innovations and new data, with Chief Movement Officer Arnold Schwarzenegger leading the charge at AAOS 2026.

With $400M in 2025 sales, Immunocore now leverages its KIMMTRAK success to fund a high-stakes pivot into broader cancers, HIV, and autoimmune disease.

With the appointment of TechTarget co-founder Don Hawk, Life Science Connect is set to import a proven B2B intent data playbook into the life sciences.

A landmark partnership aims to bring precision cancer therapy, or Theranostics, to millions in underserved nations, backed by a major WHO resolution.

By fitting into existing hospital rooms, Mevion's newly CE-Marked proton therapy system aims to slash costs and expand access to advanced cancer treatment.

Japan becomes the first nation outside Israel to approve Alpha DaRT, a highly precise therapy for untreatable head and neck cancers. Here’s what it means.

New FDA-cleared Persona PLUS technology promises to increase plasma yields per donor, tackling the growing global demand for life-saving therapies.

Promising trial data for onvansertib offers new hope for colorectal cancer patients, yet leadership changes and financial hurdles cloud the path forward.

The life sciences giant's significant dividend hike underscores its robust financial health and commitment to growth, even as it pursues major acquisitions.

After a major trial miss sent its stock tumbling, GRAIL will face investors to pitch its vision for the future of early cancer detection technology.

A Florida jury found Publix 100% liable for a fall that led to three spinal surgeries for a young mother, rejecting the company's $600k offer.

A new Ontario program is giving breast cancer patients access to a life-changing drug a year sooner, setting a potential new standard for Canada.

Verdiva Bio's VRB-101 aims to be the first once-weekly oral GLP-1, a potential game-changer for patients tired of daily pills and injections.

A massive new study finds ECGs save young lives, questioning UK policy as 12 die weekly from hidden heart conditions. Is repeat screening the answer?

The global testing giant's latest move deepens its U.S. consulting services, signaling a major strategic shift in a competitive North American market.